(Q44239880)

1 December 2017

title

Combination therapy for dyslipidemia: safety and regulatory considerations (English)

1 reference

1 December 2017

1 reference

Michael H Davidson

1

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

American Journal of Cardiology

1 December 2017

published in

1 reference

1 December 2017

volume

90

1 reference

1 December 2017

issue

10B

1 reference

1 December 2017

page(s)

50K-60K

1 reference

New statins and new doses of older statins

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on human gut mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

The impact of the National Cholesterol Education Program Adult Treatment Panel III guidelines on drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Does differing metabolism by cytochrome p450 have clinical importance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Plasma concentrations of active simvastatin acid are increased by gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Controversy surrounding the safety of cerivastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Pharmacokinetics of the combination of fluvastatin and gemfibrozil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Mechanistic studies on metabolic interactions between gemfibrozil and statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

The myotoxicity of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Lovastatin, nicotinic acid, and rhabdomyolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Rhabdomyolysis and HMG-CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Safety of combined pravastatin-gemfibrozil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902970-3

10.1016/S0002-9149(02)02970-3

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference